SQI Diagnostics, Inc. CEO Mr. Robert L. Chioini stated, “Within our organ transplant, autoimmune disease, and serological testing business units we have multiple products in clinical development, and we believe these advanced tests have the potential to offer patients and consumers significant benefit once they receive regulatory approval.

Oncimmune CEO dam M Hill said: “We are pleased to announce this partnership between our ImmunoINSIGHTS business and another world-leading biopharmaceutical company.”

Micron Biomedical reports their applicator-free technology is well-suited for the administration of vaccines and, in particular, for measles-rubella vaccination in low- and middle-income countries.

ImmunoGen, Inc. is a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer.

Project RE will focus on finding therapies to tackle viral entry and replication and is co-led between Mila (Quebec AI Institute) and Relation Therapeutics, with the overall scientific direction by Mila founder Professor Yoshua Bengio.